Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Zai Lab
ISIN US98887Q1040
|WKN A2DX1V
Market cap (in EUR)
2,139 m
Country
China
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals China
Financials
Key metrics
| Market capitalisation, EUR | 2,139 m |
| EPS, EUR | -1.42 |
| P/B ratio | 3.6 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 409 m |
| Net income, EUR | -156 m |
| Profit margin | -38.15% |
What ETF is Zai Lab in?
There are 11 ETFs which contain Zai Lab. All of these ETFs are listed in the table below. The ETF with the largest weighting of Zai Lab is the L&G Pharma Breakthrough UCITS ETF.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.